Embecta Corp.
Embecta (Nasdaq: EMBC) is a global medical device company focused primarily on products for people living with diabetes. Its portfolio includes conventional and safety pen needles, insulin syringes and safety injection devices used to administer insulin and other diabetes medications. Customers include people with… From the company’s description.
Over the twelve months to Jun 30, 2026, Embecta Corp. reported revenue of $1.02B, down 7.6% from a year earlier, and net income of $87.50M. Its operating margin was 21.9%, and operations generated $174.10M in cash. In fiscal 2025, it reported revenue of $1.08B, down 3.8% from fiscal 2024, and net income of $95.40M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Embecta Corp. does
In the company’s own words
Embecta (Nasdaq: EMBC) is a global medical device company focused primarily on products for people living with diabetes. Its portfolio includes conventional and safety pen needles, insulin syringes and safety injection devices used to administer insulin and other diabetes medications. Customers include people with diabetes, healthcare providers, hospitals, pharmacies, retail and institutional distributors, and other care channels. Embecta sells its products in more than 100 countries and reports its business as a single operating business, rather than through multiple reportable segments. In fiscal 2025, pen needles generated approximately $784 million, or 73% of total net revenue; the company had approximately 1,850 regular employees worldwide as of September 30, 2025. Embecta became an independent, publicly traded company in 2022 when Becton, Dickinson and Company spun off its diabetes care business. Its website is www.embecta.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- PARSIPPANY, NJ
- Fiscal year end
- September
- CIK
- 1872789
- SIC
- 3841
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Embecta Corp. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Embecta Corp.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Embecta Corp.’s bonds, as funds hold them
Funds report holding 2 issues of Embecta Corp.’s debt, $102.41M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 5.43%, maturing 2030 to 2030.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Embecta Corp. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Embecta Corp.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Embecta Corp.'s last four quarterly filings that the numbers alone won't show?”